Terms: = Bone cancer AND OMD, osteoadherin, 4958, ENSG00000127083, Q99983, SLRR2C
22 results:
1. Prospective Characterization of Circulating Tumor Cell Kinetics in Patients With Oligometastatic Disease Receiving Definitive Intent Radiation Therapy.
Sud S; Poellmann MJ; Hall J; Tan X; Bu J; Myung JH; Wang AZ; Hong S; Casey DL
JCO Precis Oncol; 2023 Sep; 7():e2300303. PubMed ID: 38096474
[TBL] [Abstract] [Full Text] [Related]
2. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.
Penack O; Peczynski C; Koenecke C; Polge E; Sanderson R; Yakoub-Agha I; Fegueux N; Daskalakis M; Collin M; Dreger P; Kröger N; Schanz U; Bloor A; Ganser A; Besley C; Wulf GG; Novak U; Moiseev I; Schoemans H; Basak GW; Chabannon C; Sureda A; Glass B; Peric Z
Front Immunol; 2023; 14():1252811. PubMed ID: 37828980
[TBL] [Abstract] [Full Text] [Related]
3. Differential Perspectives by Specialty on Oligometastatic Colorectal cancer: A Korean Oligometastasis Working Group's Comparative Survey Study.
Cho WK; Yoo GS; Rim CH; Jeong JU; Chie EK; Ahn YC; Cho HM; Um JW; Suh YG; Chang AR; Lee JH;
Cancer Res Treat; 2023 Oct; 55(4):1281-1290. PubMed ID: 37290481
[TBL] [Abstract] [Full Text] [Related]
4. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract] [Full Text] [Related]
5. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
[TBL] [Abstract] [Full Text] [Related]
6. Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
Frost N; Roeper J; Velthaus JL; Raspe M; Olive E; Schmittel A; Schmidt B; Wasilewski D; Onken J; Lüders H; Witzenrath M; Senger C; Böhmer D; Loges S; Griesinger F; Modest DP; Grohé C
Lung Cancer; 2022 Aug; 170():165-175. PubMed ID: 35803041
[TBL] [Abstract] [Full Text] [Related]
7. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract] [Full Text] [Related]
8. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract] [Full Text] [Related]
9. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.
Piroth MD; Krug D; Feyer P; Baumann R; Combs S; Duma MN; Dunst J; Fastner G; Fietkau R; Guckenberger M; Haase W; Harms W; Hehr T; Sedlmayer F; Souchon R; Strnad V; Budach W
Strahlenther Onkol; 2022 Jul; 198(7):601-611. PubMed ID: 35527272
[TBL] [Abstract] [Full Text] [Related]
10. Metastasis-directed Therapy in Prostate cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract] [Full Text] [Related]
11. Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry.
Tan YG; Poon RJ; Pang LJ; Villanueva A; Huang HH; Chen K; Ng TK; Tay KJ; Ho HS; Yuen JS
Urol Oncol; 2020 Aug; 38(8):682.e1-682.e9. PubMed ID: 32475745
[TBL] [Abstract] [Full Text] [Related]
12. Novel ASAP1-USP6, FAT1-USP6, SAR1A-USP6, and TNC-USP6 fusions in primary aneurysmal bone cyst.
Šekoranja D; Zupan A; Mavčič B; Martinčič D; Salapura V; Snoj Ž; Limpel Novak AK; Pižem J
Genes Chromosomes Cancer; 2020 Jun; 59(6):357-365. PubMed ID: 32011035
[TBL] [Abstract] [Full Text] [Related]
13. Primary aneurysmal bone cyst with a novel SPARC-USP6 translocation identified by next-generation sequencing.
Šekoranja D; Boštjančič E; Salapura V; Mavčič B; Pižem J
Cancer Genet; 2018 Dec; 228-229():12-16. PubMed ID: 30553465
[TBL] [Abstract] [Full Text] [Related]
14. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract] [Full Text] [Related]
15. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract] [Full Text] [Related]
16. Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Warren M; Xu D; Li X
Cancer Genet; 2017 Apr; 212-213():13-18. PubMed ID: 28449806
[TBL] [Abstract] [Full Text] [Related]
17. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.
Mithraprabhu S; Khong T; Ramachandran M; Chow A; Klarica D; Mai L; Walsh S; Broemeling D; Marziali A; Wiggin M; Hocking J; Kalff A; Durie B; Spencer A
Leukemia; 2017 Aug; 31(8):1695-1705. PubMed ID: 27899805
[TBL] [Abstract] [Full Text] [Related]
18. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.
Hill QA; Rawstron AC; de Tute RM; Owen RG
Blood; 2014 Aug; 124(8):1296-9. PubMed ID: 24939658
[TBL] [Abstract] [Full Text] [Related]
19. Study on the distribution features of bone metastases in prostate cancer.
Wang C; Shen Y
Nucl Med Commun; 2012 Apr; 33(4):379-83. PubMed ID: 22293499
[TBL] [Abstract] [Full Text] [Related]
20. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.
McTiernan A; Jinks RC; Sydes MR; Uscinska B; Hook JM; van Glabbeke M; Bramwell V; Lewis IJ; Taminiau AH; Nooij MA; Hogendoorn PC; Gelderblom H; Whelan JS
Eur J Cancer; 2012 Mar; 48(5):703-12. PubMed ID: 22036088
[TBL] [Abstract] [Full Text] [Related]
[Next]
